TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06350734

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT00655525

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered orally every day for 3 months
Study: NCT04255953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral telehealth
Description: Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
Study: NCT05150665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En-masse retraction
Description: Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew
Study: NCT04255953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral telehealth
Description: Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
Study: NCT05150665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two step Retraction
Description: Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw.
Study: NCT04148547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sooma transcranial direct current stimulation device
Description: This group received brain training through transcranial direct current for 20 minutes.
Study: NCT04255953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual
Study: NCT04148547

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sooma transcranial direct current stimulation device
Description: This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
Study: NCT02329327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet
Description: There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
Study: NCT04560959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
Study: NCT00914225

Intervention type: OTHER
Intervention: Bednets and Water Purification
Description: Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
Study: NCT00296855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasovist (BAY86-5283, MS-325)
Description: All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
Study: NCT02473185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Cross-over

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Cross-over
Study: NCT01374022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART Strategy
Description: Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARDSNet Strategy
Description: Conventional mechanical ventilation strategy.
Study: NCT01190813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/Carbidopa
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Two hours of daily patching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patching
Description: Two hours of daily patching
Study: NCT02539017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo
Description: Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo
Description: Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
Study: NCT02021214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02047279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maze procedure
Description: The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maze procedure
Description: The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve surgery
Description: For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
Study: NCT01281839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Study: NCT02047279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mitral valve surgery
Description: For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
Study: NCT01281839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study: NCT01137578

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasounds to be performed on children with central venous catheters

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasounds to be performed on children with central venous catheters

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasounds to be performed on children with central venous catheters

Intervention type: DRUG
Group type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters

Intervention type: DRUG
Group type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters

Intervention type: DRUG
Group type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging without Contrast
Description: Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging without Contrast
Description: Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging without Contrast
Description: Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
Study: NCT04179916

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: stimulation in virtual reality
Description: HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes.
Study: NCT04409171

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Study: NCT02865512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for the management of postoperative pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for the management of postoperative pain
Study: NCT04990011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioXclude amnion chorion membrane
Description: The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
Study: NCT04398823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sclerosing foam of Lauromacrogol
Description: Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sclersing liqiud of Lauromacrogol
Description: Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
Study: NCT02199223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib + panitumumab
Study: NCT01152814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal flu vaccine
Description: This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
Study: NCT01259089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor AUY922
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Undergo image-guided needle biopsy (correlative studies)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02229851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
Study: NCT02047279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left atrial reduction
Description: The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
Study: NCT02683980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis Pulse P120H and Xpeeda side firing fiber
Study: NCT01190085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Study: NCT00853944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
Study: NCT02632604

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Description: 40 hours of a computerized cognitive training, given 1 hour daily
Study: NCT01190085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Study: NCT06609486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement group
Description: In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device.
Study: NCT01683604

Intervention type: OTHER
Intervention: Observational study
Study: NCT01466738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV-16 (100 TCID50)
Description: Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV-16 (1000 TCID50)
Description: Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
Study: NCT02440061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic human AG
Description: Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic human AG
Description: Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Arginine hydrochloride (5 g) intravenously over 45 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Arginine hydrochloride (5 g) intravenously over 45 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline solution
Description: A continuous infusion of 0.9% saline solution (control) for 4.5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline solution
Description: A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
Study: NCT02025283

Intervention type: PROCEDURE
Intervention: Group Decompression or Group Nucleoplasty
Description: Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]

Intervention type: PROCEDURE
Intervention: Group Decompression or Group Nucleoplasty
Description: Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]
Study: NCT03127319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib docetaxel zoledronic
Description: apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel zoledronic
Description: docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT02107846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-112
Study: NCT03213847

Intervention type: DEVICE
Group type: OTHER
Intervention: Superb microvascular imaging (SMI) (Toshiba)
Description: to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
Study: NCT02260960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 (Triglyceride form)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 (Triglyceride form)
Study: NCT02176369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
Study: NCT00901043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut supplementation
Description: Eight weeks of walnut supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ad lib diet
Description: Eight weeks without walnut supplementation
Study: NCT04178304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy with 25% Dextrose
Description: Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
Study: NCT04018495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Tracker
Description: Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
Study: NCT00616746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 1.0 microg/kg/min IV x 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: IV
Study: NCT03000946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
Study: NCT04441346

Intervention type: RADIATION
Intervention: Echocardiography
Description: test that uses high frequency sound waves (ultrasound) to make pictures of your heart.

Intervention type: RADIATION
Intervention: Echocardiography
Description: test that uses high frequency sound waves (ultrasound) to make pictures of your heart.

Intervention type: RADIATION
Intervention: Echocardiography
Description: test that uses high frequency sound waves (ultrasound) to make pictures of your heart.